MedImmune

We are committed to innovation and constantly pushing the boundaries of science

~2,200

MedImmune employees globally

>120

Biologics in research and development

178

Publications in 2014

Our capabilities

Personalised medicine at MedImmune

Committed to driving innovation, no matter where it hides

Commitment to science

Our commitment to science is reflected in our track record of publications. Here are a few recent examples of high impact and high quality publications co-authored by AstraZeneca and/or MedImmune scientists.

Efficacy and safety of durvalumab in locally advanced or metastatic urothelial carcinoma: updated results from a phase 1/2 open-label study

Published: 17 August 2017

Area: Oncology

AstraZeneca/MedImmune author: Joyce Antal, Xiaoping Jin, Ashok Gupta    

In silico design of context-responsive mammalian promoters with user-defined functionality

Published: 30 August 2017

Area: R&D (Early Development)

AstraZeneca/MedImmune author:  Suzanne Gibson, Diane Hatton

Fractionated dosing improves preclinical therapeutic index of pyrrolobenzodiazepine-containing antibody drug conjugates

Published: 23 August 2017

Area: Oncology

AstraZeneca/MedImmune author: Mary Jane Masson Hinrichs, Pauline Ryan, Bo Zheng

Gut check on diabesity: leveraging gut mechanisms for the treatment of type 2 diabetes and obesity

Published: 10 August 2017

Area: CVMD

AstraZeneca/MedImmune author:  Sarah Will, David Hornigold, David Baker

Role of CD11c+ T-bet+ B cells in human health and disease

Published: 11 June 2017

Area: RIA

AstraZeneca/MedImmune author:  Jodi Karnell, Varsha Kumar, Jingya Wang, Shu Wang, Elisaveta Voynova, Rachel Ettinger

Expression of PD-L1 and other immunotherapeutic targets in thymic epithelial tumors

Published: 03 August 2017

Area: Oncology

AstraZeneca/MedImmune author:  Keith Steele

High-throughput quantitation of Fc-containing recombinant proteins in cell culture supernatant by fluorescence polarization spectroscopy

Published: 01 October 2017

Area: R&D (Early Development)

AstraZeneca/MedImmune author:  Mike Jenns

A phase 1 study to evaluate the safety and pharmacokinetics of MEDI8852, an anti-influenza A monoclonal antibody, in healthy adult volunteers

Published: 22 August 2017

Area: Infection

AstraZeneca/MedImmune author: Raburn Mallory

Targeting phosphatase-dependent proteoglycan switch for rheumatoid arthritis therapy

Published: 20 May 2015

Area: Inflammation and Autoimmunity 

AstraZeneca/MedImmune author: Tomas Mustelin

IL-33 drives airway hyper-responsiveness through IL-13-mediated mast cell: airway smooth muscle crosstalk

Published: 16 March 2015

Area: Respiratory

AstraZeneca/MedImmune author:  Richard May (MedImmune)  

Low-frequency coding variants at 6p22.2-6p21.31 and 20q11.21 are associated with lung cancer risk in Chinese populations

Published: 7 May 2015

Area: Oncology

AstraZeneca/MedImmune author: Brandon Higgs